The pharmaceutical industry continues to be a hotbed of patent innovation. Activity is driven by the evolution of treatment paradigms, and the gravity of unmet needs, as well as the growing importance of technologies such as pharmacogenomics, digital therapeutics, and artificial intelligence. In the last three years alone, there have been over 787,000 patents filed and granted in the pharmaceutical industry, according to GlobalData’s report on Cell & gene therapy in pharma: recombinant adeno-associated virus (AAV) gene therapy. Buy the report here.
Smarter leaders trust GlobalData
According to GlobalData’s Technology Foresights, which uses over 668,000 patents to analyze innovation intensity for the pharmaceutical industry, there are 80+ innovation areas that will shape the future of the industry.
Recombinant AAV gene therapy is a key innovation area in cell & gene therapy
Recombinant AAV gene therapy is a technique that uses recombinant adeno-associated viruses (AAVs) as vectors to deliver therapeutic genes to target tissues. AAVs have gained attention due to their ability to provide long-term expression of therapeutic genes without inducing an immune response. Recombinant AAVs are engineered to carry specific therapeutic genes and are used to treat a range of genetic and acquired diseases.
GlobalData’s analysis also uncovers the companies at the forefront of each innovation area and assesses the potential reach and impact of their patenting activity across different applications and geographies. According to GlobalData, there are 110+ companies, spanning technology vendors, established pharmaceutical companies, and up-and-coming start-ups engaged in the development and application of recombinant AAV gene therapy.
Key players in recombinant AAV gene therapy – a disruptive innovation in the pharmaceutical industry
‘Application diversity’ measures the number of applications identified for each patent. It broadly splits companies into either ‘niche’ or ‘diversified’ innovators.
‘Geographic reach’ refers to the number of countries each patent is registered in. It reflects the breadth of geographic application intended, ranging from ‘global’ to ‘local’.
Patent volumes related to recombinant AAV gene therapy
| Company | Total patents (2010 - 2022) | Premium intelligence on the world's largest companies |
| Takeda Pharmaceutical | 164 | Unlock Company Profile |
| Encoded Therapeutics | 115 | Unlock Company Profile |
| Genethon | 107 | Unlock Company Profile |
| BioMarin Pharmaceutical | 90 | Unlock Company Profile |
| Sanofi | 77 | Unlock Company Profile |
| Esteve Pharmaceuticals | 68 | Unlock Company Profile |
| Centre National de la Recherche Scientifique | 67 | Unlock Company Profile |
| Bayer | 61 | Unlock Company Profile |
| Children's Hospital of Philadelphia | 57 | Unlock Company Profile |
| Nationwide Children's Hospital | 51 | Unlock Company Profile |
| Applied Genetic Technologies | 49 | Unlock Company Profile |
| RegenxBio | 49 | Unlock Company Profile |
| Astellas Pharma | 46 | Unlock Company Profile |
| Sangamo Therapeutics | 45 | Unlock Company Profile |
| St. Jude Children’s Research Hospital | 44 | Unlock Company Profile |
| Homology Medicines | 38 | Unlock Company Profile |
| Biogen | 36 | Unlock Company Profile |
| Decibel Therapeutics | 34 | Unlock Company Profile |
| Eli Lilly | 33 | Unlock Company Profile |
| Adverum Biotechnologies | 33 | Unlock Company Profile |
| Syncona | 32 | Unlock Company Profile |
| Pfizer | 31 | Unlock Company Profile |
| Massachusetts Eye and Ear Infirmary | 30 | Unlock Company Profile |
| Benitec Biopharma | 30 | Unlock Company Profile |
| Eyeserv | 30 | Unlock Company Profile |
| Regeneron Pharmaceuticals | 29 | Unlock Company Profile |
| Voyager Therapeutics | 28 | Unlock Company Profile |
| UniQure | 28 | Unlock Company Profile |
| Fondazione Telethon | 28 | Unlock Company Profile |
| Tenaya Therapeutics | 27 | Unlock Company Profile |
| Verneuil Participations | 22 | Unlock Company Profile |
| Precision Biosciences | 22 | Unlock Company Profile |
| Rocket Pharmaceuticals | 20 | Unlock Company Profile |
| Life Sciences Research Partners VZW | 20 | Unlock Company Profile |
| Generation Bio | 20 | Unlock Company Profile |
| 4D Molecular Therapeutics | 19 | Unlock Company Profile |
| Genepod Therapeutics | 19 | Unlock Company Profile |
| AVROBIO | 16 | Unlock Company Profile |
| Daiichi Sankyo | 15 | Unlock Company Profile |
| SparingVision | 15 | Unlock Company Profile |
| MeiraGTx | 14 | Unlock Company Profile |
| Children's Medical Center | 14 | Unlock Company Profile |
| Ecole Polytechnique Federale de Lausanne | 14 | Unlock Company Profile |
| Ultragenyx Pharmaceutical | 14 | Unlock Company Profile |
| ToolGen | 13 | Unlock Company Profile |
| NeuExcell Therapeutics | 13 | Unlock Company Profile |
| Vivet Therapeutics | 12 | Unlock Company Profile |
| Sarepta Therapeutics | 12 | Unlock Company Profile |
| American Gene Technologies International | 12 | Unlock Company Profile |
| UCB | 12 | Unlock Company Profile |
Source: GlobalData Patent Analytics
Takeda Pharmaceutical (Takeda) is one of the leading patent filers in recombinant AAV gene therapy. Takeda is a research-based pharmaceutical company, which focuses on the discovery, development, manufacturing, marketing, commercialization, import and export of medications. It provides treatment for inflammatory bowel disease, acid-related diseases, motility disorders and liver diseases; hemophilia and hereditary bleeding disorders; primary immunodeficiency and multifocal motor neuropathy; major depressive disorder and attention-deficit hyperactivity disorder. Its cancer treatment encompasses multiple myeloma, mantle cell lymphoma, non-small cell lung cancer and chronic myeloid leukemia. Encoded Therapeutics and Genethon are some of the other key patent filers in recombinant AAV gene therapy.
In terms of application diversity, Pfizer leads the pack, while Biogen and Sanofi stood in the second and third positions, respectively. By means of geographic reach, Esteve Pharmaceuticals held the top position, followed by Adverum Biotechnologies and Sangamo Therapeutics.
To further understand the key themes and technologies disrupting the pharmaceutical industry, access GlobalData’s latest thematic research report on Pharmaceutical.
Premium Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.
GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.
GlobalData’s Patent Analytics tracks patent filings and grants from official offices around the world. Textual analysis and official patent classifications are used to group patents into key thematic areas and link them to specific companies across the world’s largest industries.
